RECENT PLACEMENT

Occam Places Jeb Ledell as COO at Aveo Oncology

Occam Places Jeb Ledell as COO at Aveo Oncology

AVEO Oncology (Nasdaq: AVEO) is a commercial stage, oncology-focused biopharmaceutical company. Aveo was acquired by LG Chem for $600M in October of 2022.

In late 2021, Occam placed Jeb Ledell as COO of AVEO. Jeb joined AVEO from Enzyvant Therapeutics, a biotech company dedicated to developing novel, transformative regenerative therapies with rare diseases, where he served as COO. Prior to Enzyvant, Jeb served as COO at Compass Therapeutics and Horizon Discovery Group.

‍

Recent Placements

  1. Carolyn Haley as COO at F-Prime Capital
  2. Chau Cheng as VP of Investor Relations & Corporate Communications at Cytomx
  3. Bryan Stuart as CEO of Atavistik
  4. Bimal Shah as CFO of Corium
  5. Bell Zhong as CFO at Neomorph
About Occam Global

Occam Global is a trusted executive search, consulting, and investment partner for leaders and investors shaping the future of life sciences, deep tech, and venture capital. Since 2012, we’ve helped build high-performing teams and advised visionary companies from stealth to public markets. Our success stems from exceptional access to rare talent, deep sector expertise, and a commitment to results guided by elevated ethics and enlightened aggression.